Pilot Study of CyclaPlex Implant, an Enhanced Suture and Button Implant Device in Hallux Valgus Deformity (CO001)
Primary Purpose
Hallux Valgus
Status
Unknown status
Phase
Phase 1
Locations
Israel
Study Type
Interventional
Intervention
Cyclaplex bone anchor
Sponsored by
About this trial
This is an interventional treatment trial for Hallux Valgus
Eligibility Criteria
Inclusion Criteria
- Adult males and female subjects, aged 20 to 75 years old, inclusive, at screening visit
- Subject weighing <100 kg and body mass index (BMI) <32 kg/m2
- Subjects with confirm diagnosis of HV deformity based on radiography assessment of IMA > 12 º and less or equal to 20degree.
- Subjects who would need osteotomy of the 1st MT as part of their surgery.
- Able and willing to comply with the requirements of the protocol.
- Able to understand and sign written informed consent to participate in the study
Exclusion criteria
- Contraindication to implantation procedure
- History of: Diabetes mellitus,Claudication vascular disease or known Peripheral Vascular Disease,Rheumatoid disease no palpable pulse (DP or PT),- Gout or any systemic inflammatory arthropathy,Osteoarthritis of first metatarsal,Neurological conditions associated with spasticity,No prior operation at 1st and 2nd Metatarsals
- Osteoporosis
- Secondary metatarsal complications including:Fracture (past or present), Aseptic necrosis or any deformity of 2nd MTH,Subject currently enrolled in or has not yet completed at least 30 days since ending
- Any condition that may jeopardize study participation (e.g. abnormal clinical or laboratory finding), the interpretation of study results or may impede the ability to obtain informed consent (e.g., mental condition)
Sites / Locations
- MMCRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
CYCLAPLEX bone anchors
Arm Description
Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia. The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required. Subjects will be followed-up for 50 weeks post-procedure.
Outcomes
Primary Outcome Measures
Percent of subjects with 1st IMA ≤9º or reduction of more than 7º in the 1st IMA compared to Base line at last observed value (LOV).
Secondary Outcome Measures
General Improvement as assessed by American Orthopaedic Foot and Ankle Society Hallux Metatarsophalangeal-lnterphalangeal Scale (AOFAS HMIS) score
The AOFAS score results at each visit will be evaluated and compared to other known studies published
Pain and Functional assessment [Foot Function Index (FFI)]
Pain and functional index will be assesed for complete results and separately for pain and functionality
Time to full weight bear, to use of regular shoes and fashion shoes.
Reduction in 1st IMA from baseline to LOV
Number and type of Adverse Events
Adverse events will be evaluated for their severity and frequency
Complications at surgery
Number and type of complications at surgery will be evaluated
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01879150
Brief Title
Pilot Study of CyclaPlex Implant, an Enhanced Suture and Button Implant Device in Hallux Valgus Deformity
Acronym
CO001
Official Title
Single Center, Open-label, Single Arm, Study Designed to Evaluate Safety, Tolerability and Efficacy of CyclaPlex Implant and Tools for Correction of First Inter-metatarsal Angle in Subjects Suffering From Hallux Valgus Deformity
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Unknown status
Study Start Date
June 2013 (undefined)
Primary Completion Date
February 2014 (Anticipated)
Study Completion Date
September 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Meir Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Single center, open-label, single arm, pilot study designed to evaluate safety, tolerability and efficacy of CYCLAPLEX device, a minimal invasive enhanced suture and button implant and surgery tools for correction of inter-metatarsal angle in subjects suffering from mild to moderate Hallux Valgus deformity
Detailed Description
INVESTIGATIONAL THERAPY Cycla Orthopedics Ltd has developed the CYCLAPLEX , a minimally invasive enhanced type of Suture and Button implant. It is intended to: (a) reduce the intermetatarsal angle (IMA) between 1MT and 2MT without osteotomy osteotomy b) reduce the risk of 2MT fractures (d) perform the implantation procedure in an easy and safe way.
The CYCLAPLEX predicated device is the "Suture and Button" type MiniTightrope. It is based on Mini Tightrope clinical experience, however with additional features to increase safety and functionality.
The CyclaPlex device comprise of two bone holders ('Anchors ') connected by a metal cord. The cord is connected to the buttons by crimp method as part of the surgery procedures The bone holders are T shape screws that are screwed into the bones after drilling holes across the 2 metatarsals. The gap in the bone as a result of the drilling is filled by the enhanced T shape buttons (screws). A nut is residing internally as part of the 1st met anchor structure. The IMA is reduced using specially designed tensioning tool CyclaPlex device is indicated for reducing intermetatarsal angles in cases where IMA is less than 200 eliminating the need for the traditional 1st metatarsal osteotomy. It used in conjunction with traditional release of the lateral MTP joint capsular structures and removal of the medial eminence as well as regular HVA reduction procedures such as AKIN.
The 2nd Metatarsal fracture risk is reduced due multiple/ accumulated factors:
(i) The hole drilled at 2nd metatarsal had been reduced significantly (ii) The hole is filled by conical screw and head. This firm anchoring method enable to distribute the horizontal forces applied during gate.
(iii) The metal screw type device enables bone growth over it and strengthen the bone at that area.
(iv) The connecting cord is housed inside the screw and has no direct touch with the bone, in both, 2nd and 1st metatarsals.
The device is delivered sterilized ( steam sterilization) double bag residing in cardboard box.
Dedicated assistive tools for multiple use are provided as well housed in a special tray intended for surgery room steam sterilization. The tools comprise of Aiming Drilling Guide,, screw driver for anchors insertion, Tensioning tool for reduction of the IMA, Crimping tool, cutter, single use drill bits
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hallux Valgus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
CYCLAPLEX bone anchors
Arm Type
Experimental
Arm Description
Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.
The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.
Subjects will be followed-up for 50 weeks post-procedure.
Intervention Type
Device
Intervention Name(s)
Cyclaplex bone anchor
Intervention Description
Device implantation
Primary Outcome Measure Information:
Title
Percent of subjects with 1st IMA ≤9º or reduction of more than 7º in the 1st IMA compared to Base line at last observed value (LOV).
Time Frame
6 months follow up and 12 months follow up
Secondary Outcome Measure Information:
Title
General Improvement as assessed by American Orthopaedic Foot and Ankle Society Hallux Metatarsophalangeal-lnterphalangeal Scale (AOFAS HMIS) score
Description
The AOFAS score results at each visit will be evaluated and compared to other known studies published
Time Frame
6 months, 12 months
Title
Pain and Functional assessment [Foot Function Index (FFI)]
Description
Pain and functional index will be assesed for complete results and separately for pain and functionality
Time Frame
6 months 12 months
Title
Time to full weight bear, to use of regular shoes and fashion shoes.
Time Frame
12 months
Title
Reduction in 1st IMA from baseline to LOV
Time Frame
6 months, 12 months
Title
Number and type of Adverse Events
Description
Adverse events will be evaluated for their severity and frequency
Time Frame
6 months, 12 months
Title
Complications at surgery
Description
Number and type of complications at surgery will be evaluated
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
1st intermetatarsal forces at time of implantation
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Adult males and female subjects, aged 20 to 75 years old, inclusive, at screening visit
Subject weighing <100 kg and body mass index (BMI) <32 kg/m2
Subjects with confirm diagnosis of HV deformity based on radiography assessment of IMA > 12 º and less or equal to 20degree.
Subjects who would need osteotomy of the 1st MT as part of their surgery.
Able and willing to comply with the requirements of the protocol.
Able to understand and sign written informed consent to participate in the study
Exclusion criteria
Contraindication to implantation procedure
History of: Diabetes mellitus,Claudication vascular disease or known Peripheral Vascular Disease,Rheumatoid disease no palpable pulse (DP or PT),- Gout or any systemic inflammatory arthropathy,Osteoarthritis of first metatarsal,Neurological conditions associated with spasticity,No prior operation at 1st and 2nd Metatarsals
Osteoporosis
Secondary metatarsal complications including:Fracture (past or present), Aseptic necrosis or any deformity of 2nd MTH,Subject currently enrolled in or has not yet completed at least 30 days since ending
Any condition that may jeopardize study participation (e.g. abnormal clinical or laboratory finding), the interpretation of study results or may impede the ability to obtain informed consent (e.g., mental condition)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elkahn Eliev, MD
Organizational Affiliation
MMC orthopedic department physician
Official's Role
Principal Investigator
Facility Information:
Facility Name
MMC
City
Kfar Saba
ZIP/Postal Code
44281
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liraz Elazar
Phone
0509291083
Email
Liraz.Elazar@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Elkahn Eleiv, MD
Phone
0545900119
Email
'gibor5@gmail.com'
First Name & Middle Initial & Last Name & Degree
Victor Feldman, MD
First Name & Middle Initial & Last Name & Degree
Jonathan Koch, MD
12. IPD Sharing Statement
Learn more about this trial
Pilot Study of CyclaPlex Implant, an Enhanced Suture and Button Implant Device in Hallux Valgus Deformity
We'll reach out to this number within 24 hrs